Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Nur Nicholson Sells 825 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) insider Nur Nicholson sold 825 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total value of $24,354.00. Following the sale, the insider now directly owns 83,664 shares in the company, valued at $2,469,761.28. This trade represents a 0.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Nur Nicholson also recently made the following trade(s):

• On Wednesday, January 22nd, Nur Nicholson sold 3,948 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.43, for a total value of $120,137.64.
• On Friday, January 17th, Nur Nicholson sold 2,145 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total value of $64,264.20.

Apellis Pharmaceuticals Stock Down 1.8 %

NASDAQ:APLS traded down $0.52 on Monday, reaching $28.49. The stock had a trading volume of 1,501,925 shares, compared to its average volume of 1,930,394. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a 50-day moving average of $32.21 and a 200 day moving average of $32.76. The stock has a market cap of $3.54 billion, a P/E ratio of -14.03 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to analysts' expectations of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business's quarterly revenue was up 78.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.17) earnings per share. On average, research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Needham & Company LLC cut their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Morgan Stanley started coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They set an "equal weight" rating and a $31.00 price objective for the company. Wells Fargo & Company dropped their price objective on Apellis Pharmaceuticals from $43.00 to $30.00 and set an "equal weight" rating for the company in a report on Wednesday, November 6th. Piper Sandler dropped their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a "neutral" rating for the company in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group downgraded Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $36.00 price objective for the company. in a report on Tuesday, December 17th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wolverine Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $27,000. True Wealth Design LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $27,000. Capital Performance Advisors LLP acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $56,000. KBC Group NV raised its stake in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company's stock valued at $76,000 after purchasing an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company's stock valued at $130,000 after purchasing an additional 781 shares in the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).